Titulo:
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer.
.
Sumario:
Introducción: Cada año en el Congreso de la Sociedad Americana de Oncología Médica (ASCO) se convocan los expertos más importantes del mundo en las disciplinas interesadas en las neoplasias malignas. La hematología oncológica tiene una representación robusta con una relevancia creciente año a año. Se hace una pequeña revisión de los resúmenes y presentaciones más significativas de la hematología oncológica en el ASCO 2013. Metodología: Se lleva a cabo una selección semiestructurada de los resúmenes y presentaciones en el ASCO 2013 con mayor relevancia según el tipo de investigación clínica, impacto potencial a la práctica clínica, prueba de principios de mecanismos de acción novedosos y difusión mediática durante el Congreso, con énfasis en... Ver más
Guardado en:
2256-2877
2256-2915
2
2013-07-01
23
31
Mauricio Lema - 2013
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
| id |
metarevistapublica_acho_revistacolombianadehematologiayoncologia_27_article_341 |
|---|---|
| record_format |
ojs |
| spelling |
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer. Hematology at ASCO 2013 : building bridges to conquer cancer. Introducción: Cada año en el Congreso de la Sociedad Americana de Oncología Médica (ASCO) se convocan los expertos más importantes del mundo en las disciplinas interesadas en las neoplasias malignas. La hematología oncológica tiene una representación robusta con una relevancia creciente año a año. Se hace una pequeña revisión de los resúmenes y presentaciones más significativas de la hematología oncológica en el ASCO 2013. Metodología: Se lleva a cabo una selección semiestructurada de los resúmenes y presentaciones en el ASCO 2013 con mayor relevancia según el tipo de investigación clínica, impacto potencial a la práctica clínica, prueba de principios de mecanismos de acción novedosos y difusión mediática durante el Congreso, con énfasis en los expuestos en las secciones los Hitos del día. Se realiza un comentario sobre los resúmenes y presentaciones elegidos. Resultados: Se seleccionaron 22 resúmenes/presentaciones que tienen como foco la hematología oncológica. Se resaltó la importancia de la terapia dirigida contra dianas como la tirosina quinasa tipo Bruton, el Bcl-2 y la subunidad delta de la PI3K en neoplasias linfoides B. Se expanden los usos potenciales de la lenalidomida a linfoma del manto. Se exploran medicamentos y esquemas de tratamiento específicamente diseñados para neoplasias linfoides de células T, como los nuevos inhibidores de histona deacetilasa, entre ellos el belinostat. En mieloma múltiple, se discuten los estudios que difunden el uso de la lenalidomida de mantenimiento postrasplante, así como la eficacia de los agentes carfilzomib, MLN9708, pomalidomida o elotuzumab. Se revisan estudios sobre la importancia del seguimiento estricto en los linfomas ya tratados. Conclusión: Muchos y grandes avances se presentan en el ASCO 2013, constituyéndolo en una fuente importante de diseminación de avances en la hematología oncológica. Introduction: The Meeting of the American Society of Clinical Oncology (ASCOm) gathers every year the leading world experts in malignant diseases. An ever increasing share of the ASCOm is accounted by abstracts and presentations on hematologic oncology (HO). In this article, brief commentaries are presented on key abstracts submitted to the ASCOm of 2013 on HO. Methods: Key abstracts submitted to the 2013’s ASCOm on HO were selected based on type of research (favoring clinical trials), potential clinical relevance, translational medicine (favoring proof of principle of novel targets) and media attention, with emphasis on those selected for discussion during the Highlights of the day sessions during the ASCOm. A short description and commentary is made of the selected abstracts. Results: Twenty two abstracts on HO were selected. Of note, several abstracts underscore the therapeutic potential of novel targeted agents against Bruton tyrosine kinases, PI3k delta and Bcl-2 in mature B-cell malignancies. The efficacy of lenalidomide in heavily-pretreated mantle-cell lymphoma is also presented. Newer combination chemotherapies and targeted agents against T-cell malignancies including belinostat, a novel histone de acetylase inhibitor, were presented. In multiple myeloma, post high-dose melphalan maintenance with lenalidomide appears to improve clinical outcomes. Also in multiple myeloma, several new agents appear to be safe and effective including carfilzomib and the oral MLN9708 (proteasome inhibitors), pomalidomide (a new imid) and the anti CD38, elotuzumab. Two abstracts suggest that routine follow-up imaging studies after definitive therapy of both Hodgkin’s and aggressive non-Hodgkin’s lymphoma may be futile. Conclusion: The yearly ASCOm has become a relevant venue for the presentation, discussion and spread of worthwhile research in hematologic oncology. Lema, Mauricio ASCO avances hematología ASCO advances hematology 2 2 Núm. 2 , Año 2013 : Julio Artículo de revista Journal article 2013-07-01T00:00:00Z 2013-07-01T00:00:00Z 2013-07-01 application/pdf Asociación Colombiana de Hematología y Oncología (ACHO) Revista Colombiana de Hematología y Oncología 2256-2877 2256-2915 https://revista.acho.info/index.php/acho/article/view/341 10.51643/22562915.341 https://doi.org/10.51643/22562915.341 spa https://creativecommons.org/licenses/by-nc-sa/4.0 Mauricio Lema - 2013 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. 23 31 Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16. Horwitz SM, Finn I, Patel MR, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide3-kinase-δ,γ, in patients with relapsed/refractory lymphoma. J Clin Oncol. 2013;31 (suppl): abstr 8518. Spurgeon SEF, Wagner-Johnston ND, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL). J Clin Oncol. 2013;31 (suppl): abstr 8519. Leonard J, Wagner-Johnston ND, Coutre SE, et al. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): updated results from a phase I study. J Clin Oncol. 2013;31 (suppl): abstr 8500. Wagner-Johnston ND, Vos DB, Leonard J. Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol. 2013;31 (suppl): abstr 8501. Younes A, Flinn I, Berdeja JG. Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 2013;31 (suppl): abstr 8502. Seymour JF, Davids MS, Pagel JM, et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 2013;31 (suppl): abstr 7018. Witzig TE, Vose J, Zinzani PL. Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. J Clin Oncol 2013;31 (suppl); abstr 8533. Williams ME, Goy A, Sinha R, et al. Lenalidomide in relapsed/ refractory mantle cell lymphoma post-bortezomib: SUBGROUP analysis of the MCL-001 study. J Clin Oncol 2013;31 (suppl): abstr 8534. Huang H, Li XY, Li HR, et al. Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: a prospective study to compare entecavir and lamivudine. J Clin Oncol 2013;31 (suppl): abstr 8503. Thompson CA, Maurer MJ, Ghesquieres H, et al. Utility of post-therapy surveillance scans in DLBCL. J Clin Oncol 2013;31 (suppl): abstr 8504. Pingali SR, Jewel S, Havlat L, et al. Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. J Clin Oncol 2013;31 (suppl): abstr 8505. Lin T, Huang H, Yong Liang C, et al. Phase II/III randomized trial of CID-ATT with radiotherapy compared with CHOP with radiotherapy as first-line treatment for previously untreated early staging extranodal NK/T-cell lymphoma, nasal type (ENKL). J Clin Oncol 2013;31 (suppl); abstr 8508. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120(15):2973-80. Jo T, Ishida T, Takemoto S, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult Tcell leukemia-lymphoma (ATL). J Clin Oncol 2013;31 (suppl): abstr 8506. O’Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol 2013;31 (suppl): abstr 8507. Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of malignancy: analysis of the first U.S. cooperative group prospective clinical trial in asymptomatic monoclonal gammopathies (SWOG S0120). J Clin Oncol. 2013;31 (suppl): abstr 8515. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stemcell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69. Boccadoro M, Cavallo F, Ga F, et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol. 2013;31 (suppl): abstr 8509. Touzeau C, Kolb B, Hulin C, Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. J Clin Oncol. 2013;31 (suppl): abstr 8513. San-Miguel JF, Weisel KC, Moreau P, et al. MM-003: a phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX). J Clin Oncol. 2013;31 (suppl): abstr 8510. Weisel KC, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus highdose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). J Clin Oncol. 2013;31 (suppl): abstr 8527. Lonial S, Jagannath S, Moreau P, et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): updated Ph II results and Ph I/II long-term safety. J Clin Oncol. 2013;31 (suppl): abstr 8542. Lokhorst HM, Plesner TP, Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2013;31 (suppl): abstr 8512. Kumar S, Bensinger W, Zimmerman TM, et al. Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): results from a phase I study after full enrollment. J Clin Oncol. 2013;31 (suppl): abstr 8514. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-21. https://revista.acho.info/index.php/acho/article/download/341/303 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 http://purl.org/redcol/resource_type/ARTREF info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication |
| institution |
ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA |
| thumbnail |
https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png |
| country_str |
Colombia |
| collection |
Revista Colombiana de Hematología y Oncología |
| title |
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer. |
| spellingShingle |
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer. Lema, Mauricio ASCO avances hematología ASCO advances hematology |
| title_short |
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer. |
| title_full |
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer. |
| title_fullStr |
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer. |
| title_full_unstemmed |
Hematología en ASCO 2013 : creando puentes para conquistar el cáncer. |
| title_sort |
hematología en asco 2013 : creando puentes para conquistar el cáncer. |
| title_eng |
Hematology at ASCO 2013 : building bridges to conquer cancer. |
| description |
Introducción: Cada año en el Congreso de la Sociedad Americana de Oncología Médica (ASCO) se convocan los expertos más importantes del mundo en las disciplinas interesadas en las neoplasias malignas. La hematología oncológica tiene una representación robusta con una relevancia creciente año a año. Se hace una pequeña revisión de los resúmenes y presentaciones más significativas de la hematología oncológica en el ASCO 2013. Metodología: Se lleva a cabo una selección semiestructurada de los resúmenes y presentaciones en el ASCO 2013 con mayor relevancia según el tipo de investigación clínica, impacto potencial a la práctica clínica, prueba de principios de mecanismos de acción novedosos y difusión mediática durante el Congreso, con énfasis en los expuestos en las secciones los Hitos del día. Se realiza un comentario sobre los resúmenes y presentaciones elegidos. Resultados: Se seleccionaron 22 resúmenes/presentaciones que tienen como foco la hematología oncológica. Se resaltó la importancia de la terapia dirigida contra dianas como la tirosina quinasa tipo Bruton, el Bcl-2 y la subunidad delta de la PI3K en neoplasias linfoides B. Se expanden los usos potenciales de la lenalidomida a linfoma del manto. Se exploran medicamentos y esquemas de tratamiento específicamente diseñados para neoplasias linfoides de células T, como los nuevos inhibidores de histona deacetilasa, entre ellos el belinostat. En mieloma múltiple, se discuten los estudios que difunden el uso de la lenalidomida de mantenimiento postrasplante, así como la eficacia de los agentes carfilzomib, MLN9708, pomalidomida o elotuzumab. Se revisan estudios sobre la importancia del seguimiento estricto en los linfomas ya tratados. Conclusión: Muchos y grandes avances se presentan en el ASCO 2013, constituyéndolo en una fuente importante de diseminación de avances en la hematología oncológica.
|
| description_eng |
Introduction: The Meeting of the American Society of Clinical Oncology (ASCOm) gathers every year the leading world experts in malignant diseases. An ever increasing share of the ASCOm is accounted by abstracts and presentations on hematologic oncology (HO). In this article, brief commentaries are presented on key abstracts submitted to the ASCOm of 2013 on HO. Methods: Key abstracts submitted to the 2013’s ASCOm on HO were selected based on type of research (favoring clinical trials), potential clinical relevance, translational medicine (favoring proof of principle of novel targets) and media attention, with emphasis on those selected for discussion during the Highlights of the day sessions during the ASCOm. A short description and commentary is made of the selected abstracts. Results: Twenty two abstracts on HO were selected. Of note, several abstracts underscore the therapeutic potential of novel targeted agents against Bruton tyrosine kinases, PI3k delta and Bcl-2 in mature B-cell malignancies. The efficacy of lenalidomide in heavily-pretreated mantle-cell lymphoma is also presented. Newer combination chemotherapies and targeted agents against T-cell malignancies including belinostat, a novel histone de acetylase inhibitor, were presented. In multiple myeloma, post high-dose melphalan maintenance with lenalidomide appears to improve clinical outcomes. Also in multiple myeloma, several new agents appear to be safe and effective including carfilzomib and the oral MLN9708 (proteasome inhibitors), pomalidomide (a new imid) and the anti CD38, elotuzumab. Two abstracts suggest that routine follow-up imaging studies after definitive therapy of both Hodgkin’s and aggressive non-Hodgkin’s lymphoma may be futile. Conclusion: The yearly ASCOm has become a relevant venue for the presentation, discussion and spread of worthwhile research in hematologic oncology.
|
| author |
Lema, Mauricio |
| author_facet |
Lema, Mauricio |
| topicspa_str_mv |
ASCO avances hematología |
| topic |
ASCO avances hematología ASCO advances hematology |
| topic_facet |
ASCO avances hematología ASCO advances hematology |
| citationvolume |
2 |
| citationissue |
2 |
| citationedition |
Núm. 2 , Año 2013 : Julio |
| publisher |
Asociación Colombiana de Hematología y Oncología (ACHO) |
| ispartofjournal |
Revista Colombiana de Hematología y Oncología |
| source |
https://revista.acho.info/index.php/acho/article/view/341 |
| language |
spa |
| format |
Article |
| rights |
https://creativecommons.org/licenses/by-nc-sa/4.0 Mauricio Lema - 2013 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 |
| references |
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16. Horwitz SM, Finn I, Patel MR, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide3-kinase-δ,γ, in patients with relapsed/refractory lymphoma. J Clin Oncol. 2013;31 (suppl): abstr 8518. Spurgeon SEF, Wagner-Johnston ND, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL). J Clin Oncol. 2013;31 (suppl): abstr 8519. Leonard J, Wagner-Johnston ND, Coutre SE, et al. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): updated results from a phase I study. J Clin Oncol. 2013;31 (suppl): abstr 8500. Wagner-Johnston ND, Vos DB, Leonard J. Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol. 2013;31 (suppl): abstr 8501. Younes A, Flinn I, Berdeja JG. Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 2013;31 (suppl): abstr 8502. Seymour JF, Davids MS, Pagel JM, et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 2013;31 (suppl): abstr 7018. Witzig TE, Vose J, Zinzani PL. Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. J Clin Oncol 2013;31 (suppl); abstr 8533. Williams ME, Goy A, Sinha R, et al. Lenalidomide in relapsed/ refractory mantle cell lymphoma post-bortezomib: SUBGROUP analysis of the MCL-001 study. J Clin Oncol 2013;31 (suppl): abstr 8534. Huang H, Li XY, Li HR, et al. Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: a prospective study to compare entecavir and lamivudine. J Clin Oncol 2013;31 (suppl): abstr 8503. Thompson CA, Maurer MJ, Ghesquieres H, et al. Utility of post-therapy surveillance scans in DLBCL. J Clin Oncol 2013;31 (suppl): abstr 8504. Pingali SR, Jewel S, Havlat L, et al. Clinical or survival benefit to routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. J Clin Oncol 2013;31 (suppl): abstr 8505. Lin T, Huang H, Yong Liang C, et al. Phase II/III randomized trial of CID-ATT with radiotherapy compared with CHOP with radiotherapy as first-line treatment for previously untreated early staging extranodal NK/T-cell lymphoma, nasal type (ENKL). J Clin Oncol 2013;31 (suppl); abstr 8508. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120(15):2973-80. Jo T, Ishida T, Takemoto S, et al. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult Tcell leukemia-lymphoma (ATL). J Clin Oncol 2013;31 (suppl): abstr 8506. O’Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol 2013;31 (suppl): abstr 8507. Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of malignancy: analysis of the first U.S. cooperative group prospective clinical trial in asymptomatic monoclonal gammopathies (SWOG S0120). J Clin Oncol. 2013;31 (suppl): abstr 8515. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stemcell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69. Boccadoro M, Cavallo F, Ga F, et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. J Clin Oncol. 2013;31 (suppl): abstr 8509. Touzeau C, Kolb B, Hulin C, Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. J Clin Oncol. 2013;31 (suppl): abstr 8513. San-Miguel JF, Weisel KC, Moreau P, et al. MM-003: a phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX). J Clin Oncol. 2013;31 (suppl): abstr 8510. Weisel KC, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus highdose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). J Clin Oncol. 2013;31 (suppl): abstr 8527. Lonial S, Jagannath S, Moreau P, et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): updated Ph II results and Ph I/II long-term safety. J Clin Oncol. 2013;31 (suppl): abstr 8542. Lokhorst HM, Plesner TP, Gimsing P, et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2013;31 (suppl): abstr 8512. Kumar S, Bensinger W, Zimmerman TM, et al. Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): results from a phase I study after full enrollment. J Clin Oncol. 2013;31 (suppl): abstr 8514. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-21. |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2013-07-01 |
| date_accessioned |
2013-07-01T00:00:00Z |
| date_available |
2013-07-01T00:00:00Z |
| url |
https://revista.acho.info/index.php/acho/article/view/341 |
| url_doi |
https://doi.org/10.51643/22562915.341 |
| issn |
2256-2877 |
| eissn |
2256-2915 |
| doi |
10.51643/22562915.341 |
| citationstartpage |
23 |
| citationendpage |
31 |
| url2_str_mv |
https://revista.acho.info/index.php/acho/article/download/341/303 |
| _version_ |
1811200923759804417 |